Survodutide Phase 3 Results: 13% Weight Loss in 2026

Another GLP-1 name just moved from “promising pipeline” to a full Phase 3 data set.

Survodutide produced 13.0% average weight loss at 76 weeks in the 6.0 mg group of a 2026 Phase 3 trial. The 3.6 mg group averaged 12.2%, while the placebo group averaged 5.4% with the same lifestyle-counseling program.

What did the 2026 survodutide Phase 3 trial find?

SYNCHRONIZE-1 was a randomized, double-blind trial in 725 adults. People could join if they had obesity, or overweight plus at least one related health problem. The trial excluded people with diabetes.

Participants received a once-weekly injection of survodutide adjusted up to 3.6 mg, survodutide adjusted up to 6.0 mg, or placebo. Everyone also received lifestyle counseling.

Group	Average weight change at week 76	Reached at least 5% weight loss
Survodutide 3.6 mg	-12.2%	72.6%
Survodutide 6.0 mg	-13.0%	71.9%
Placebo	-5.4%	46.3%

Both primary endpoints were met. In plain English, the survodutide groups lost more weight on average, and more participants crossed the 5% mark than in the placebo group.

The 6.0 mg number was slightly larger, but the two active groups were close. That is a reminder not to turn one decimal place into a dramatic dose ranking.

What is survodutide and how does it work?

Survodutide, also called BI 456906, is an investigational peptide designed to activate two receptors:

• GLP-1, which is linked to appetite, fullness and blood-sugar control; and
• glucagon, which is involved in energy use and liver metabolism.

Think of it as two messages carried by one molecule. The goal is to combine the well-known appetite effect of GLP-1 with a second metabolic signal.

Survodutide is not a triple agonist. It does not add GIP activity. That separates it from retatrutide and from newer three-target candidates. Our BI 3034701 triple-agonist guide shows how a three-receptor program differs from a GLP-1/glucagon dual agonist.

Why did the placebo group lose 5.4%?

The placebo group did not receive “nothing.” Participants also received lifestyle counseling, and the trial’s main treatment-regimen analysis included the real-world effects of stopping treatment, using prohibited weight-loss medicines and taking longer to increase the dose.

That makes the result useful for a practical question: what happened across the assigned groups over 76 weeks, including common disruptions?

It also means this 13.0% result should not be dropped into a league table beside numbers from a different trial. Different populations, timepoints, dose plans, placebo programs and statistical methods can change the headline.

For the same reason, compare the Phase 3 result with our retatrutide Phase 3 guide by study design, not just by the largest percentage on the page.

What side effects were reported?

Gastrointestinal symptoms were the most common adverse events. The researchers described them as usually mild or moderate.

Group	Participants with gastrointestinal symptoms
Survodutide 3.6 mg	80.9%
Survodutide 6.0 mg	89.7%
Placebo	47.9%

No deaths were reported in the trial. The higher gastrointestinal-event rate in the 6.0 mg group is an important part of the result because a Phase 3 program is not only asking “does it work?” It is also asking how well people can stay on the planned treatment.

What did survodutide do for liver fat?

A separate 2026 Phase 3 study tested survodutide in adults with obesity and at-risk metabolic liver disease. At week 48, 84.2% of participants in the 6.0 mg survodutide group achieved at least a 30% reduction in liver fat under the efficacy analysis, compared with 24.3% on placebo.

That matters because the glucagon side of survodutide’s design is meant to be more than a label. The liver study gives researchers another place to look for the dual mechanism’s effect.

The obesity and liver trials answer different questions and should not be merged into one super-result. Together, they show why survodutide is being studied as a metabolic program rather than as a weight number alone.

Is survodutide approved now that Phase 3 is complete?

No. A completed positive Phase 3 trial is a major step, but it is not the same as regulatory approval. Survodutide remains investigational.

The next commercial questions include:

1. how the full Phase 3 package is reviewed;
2. whether the benefit and tolerability remain consistent across studies;
3. which dose becomes the practical target;
4. how the obesity and liver programs support each other; and
5. how manufacturing capacity keeps pace if the program advances.

That last point matters to the whole peptide market. A successful trial can increase interest quickly, but reliable supply still depends on synthesis, purification, analytical release, filling and scheduling capacity. Our 2026 peptide contract-manufacturing guide explains why buyers should reserve both material and production slots.

What should research buyers take from the survodutide news?

“Dual agonist” is not a product specification. Two peptides can both activate GLP-1 and glucagon while still being different molecules with different test methods, forms and stability requirements.

Before approving a dual-agonist research order, verify:

• the exact compound name and synonym;
• receptor profile and intended research use;
• chemical form, molecular mass and sequence record;
• batch-specific HPLC purity;
• mass-spectrometry identity;
• assay, water and residual-solvent limits when required;
• storage and shipping conditions; and
• the current COA for the supplied lot.

The bulk GLP-1 peptide supplier guide turns that list into a quote-ready buyer checklist.

The simple takeaway

Survodutide produced 13.0% average weight loss at 76 weeks in the 6.0 mg arm of a 725-person Phase 3 trial. The 3.6 mg group averaged 12.2%, and both active groups beat placebo.

The data move survodutide into the front row of 2026 dual-agonist research. It still remains investigational, and the most useful comparisons will keep the trial design, tolerability and exact molecule in view.

Discuss documented GLP-1 research supply →

Sources and further reading

• New England Journal of Medicine: SYNCHRONIZE-1 Phase 3 results
• ClinicalTrials.gov: SYNCHRONIZE-1 NCT06066515
• Nature Medicine: SYNCHRONIZE-MASLD Phase 3 trial

This article explains public research available through August 17, 2026. Survodutide is investigational and is not offered here as a medicine or for personal use.

Frequently asked questions

How much weight loss did survodutide produce in Phase 3?

In the 2026 SYNCHRONIZE-1 Phase 3 trial, average weight loss at week 76 was 12.2% with 3.6 mg and 13.0% with 6.0 mg survodutide, compared with 5.4% for placebo.

What is survodutide?

Survodutide, also called BI 456906, is an investigational once-weekly peptide that activates both the GLP-1 and glucagon receptors.

Is survodutide a triple agonist?

No. Survodutide is a dual GLP-1 and glucagon receptor agonist. Retatrutide is a different investigational peptide that also adds GIP activity and is therefore called a triple agonist.

What side effects occurred in the survodutide Phase 3 trial?

Gastrointestinal symptoms were the most common adverse events. They were usually mild or moderate and occurred in 80.9% of the 3.6 mg group, 89.7% of the 6.0 mg group and 47.9% of the placebo group.

Is survodutide approved?

No. Survodutide remains investigational. A completed Phase 3 trial is important evidence, but it is not the same as regulatory approval or availability for personal use.

What should buyers verify for a dual-agonist research peptide?

Verify the exact molecule and receptor profile, chemical form, batch number, HPLC purity, mass-spectrometry identity, assay when required, storage conditions and the current batch COA.

For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.

← More gLP-1 & weight management guides · Have a question? Start an inquiry →